Partnering
For Potential Partners
ATL-001 is in Phase 1/2 clinical development for Congenital Erythropoietic Porphyria and open for licensing discussions. ATL-002, ATL-003, and ATL-001b are earlier-stage programs available for research collaboration.
We work with biotech and pharma companies through asset-specific licensing, co-development agreements, and broader alliances, depending on the program and the partner’s priorities.
For Patients and Families
Congenital Erythropoietic Porphyria (CEP)
ATL-001, our oral treatment candidate for CEP, is currently being evaluated in a Phase 1/2 clinical trial enrolling adult patients in the US, in collaboration with Mount Sinai, Cleveland Clinic and Stanford University. Details on the trial are available at ClinicalTrials.gov (NCT07024316).
How You Can Help
Patient and family input helps us understand which aspects of CEP matter most, and supports our work with regulatory authorities and future partners. If you have CEP, are a family member of a CEP patient, or represent a patient association, contact us.